CD4 and juvenile dermatomyositis: Increased CD4+ cells, TH-17, IL-6 [41], an expanded B cell population [42], and the emerging role of natural killer cells [43], as well as the PTPN22 R620W variant, are all linked to the increased risk of developing juvenile dermatomyositis.